Published in J Virol on October 11, 2006
The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol (2010) 2.26
GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat (2009) 1.41
GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways. J Immunol (2012) 1.00
GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol (2010) 0.99
Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. Virology (2012) 0.90
The natural history of non-human GB virus C in captive chimpanzees. J Gen Virol (2010) 0.86
GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1. Oncotarget (2015) 0.75
Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard. Stat Med (2013) 0.75
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathog (2017) 0.75
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
Isolation of novel virus-like sequences associated with human hepatitis. Nat Med (1995) 4.99
Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med (2004) 4.06
Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med (2001) 3.98
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol (1996) 2.98
Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet (1997) 2.54
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50
Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol (2000) 2.32
G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion (1997) 1.96
Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet (2004) 1.78
GB virus type C/Hepatitis G virus. Semin Liver Dis (2003) 1.66
Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med (2006) 1.63
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization. J Virol (1996) 1.46
GB virus C replicates in primary T and B lymphocytes. J Infect Dis (2005) 1.44
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology (1998) 1.37
Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol (2000) 1.29
GB virus type C: a beneficial infection? J Clin Microbiol (2004) 1.24
Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology (1996) 1.18
GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microbes Infect (2003) 1.12
Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology (1998) 1.11
In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus. J Virol (1999) 1.09
The entire nucleotide sequences of two GB virus C/hepatitis G virus isolates of distinct genotypes from Japan. J Gen Virol (1997) 1.08
Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis (1998) 1.08
Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS (2005) 1.06
High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (2000) 1.06
Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins. J Virol (1998) 1.06
Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology (2003) 1.05
Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology (1997) 1.05
Detection of hepatitis G virus replication sites by using highly strand-specific Tth-based reverse transcriptase PCR. J Virol (1998) 1.01
Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Hepatology (1997) 0.98
Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays. J Med Virol (2002) 0.97
Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology (1998) 0.90
Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein. Arch Biochem Biophys (2005) 0.87
Identification of hepatitis G virus particles in human serum by E2-specific monoclonal antibodies generated by DNA immunization. J Virol (1998) 0.84
South African GB virus C isolates: interactions between genotypes 1 and 5 isolates and HIV. J Infect Dis (2005) 0.84
Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis. J Viral Hepat (1998) 0.81
Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J Med Virol (1998) 0.81
Past and present hepatitis G virus infections in areas where hepatitis C is highly endemic and those where it is not endemic. J Clin Microbiol (1998) 0.79
Evaluation of RNA and E2 antibodies in prospectively followed recipients of hepatitis G virus-infected blood. Transfusion (1999) 0.79
Interaction of synthetic peptides corresponding to hepatitis G virus (HGV/GBV-C) E2 structural protein with phospholipid vesicles. FEBS J (2005) 0.79
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med (2004) 4.06
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med (2005) 2.50
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol (2006) 1.98
Uterine massage to reduce blood loss after vaginal delivery: a randomized controlled trial. Obstet Gynecol (2013) 1.96
Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol (2007) 1.84
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis (2012) 1.80
Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet (2004) 1.78
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res (2005) 1.64
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res (2009) 1.61
Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci (2011) 1.61
Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis (2012) 1.59
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis (2003) 1.51
Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol (2004) 1.51
The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp Neurol (2009) 1.50
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol (2012) 1.50
Tourniquet device for hemorrhage control during cesarean section of complete placenta previa pregnancies. J Obstet Gynaecol Res (2013) 1.48
Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation (2004) 1.45
Restoration of connexin26 protein level in the cochlea completely rescues hearing in a mouse model of human connexin30-linked deafness. Proc Natl Acad Sci U S A (2007) 1.44
GB virus C replicates in primary T and B lymphocytes. J Infect Dis (2005) 1.44
Atoh1 directs the formation of sensory mosaics and induces cell proliferation in the postnatal mammalian cochlea in vivo. J Neurosci (2012) 1.43
Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics (2006) 1.42
GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat (2009) 1.41
Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci U S A (2009) 1.40
GB virus C: the good boy virus? Trends Microbiol (2012) 1.39
A novel mechanism for connexin 26 mutation linked deafness: cell death caused by leaky gap junction hemichannels. Laryngoscope (2006) 1.36
An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem (2009) 1.34
Targeted connexin26 ablation arrests postnatal development of the organ of Corti. Biochem Biophys Res Commun (2009) 1.32
Chronic myelogenous leukemia molecular signature. Oncogene (2003) 1.31
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr (2002) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Impaired endothelial function in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Pediatr Infect Dis J (2003) 1.26
Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol (2003) 1.25
Connexin30 null and conditional connexin26 null mice display distinct pattern and time course of cellular degeneration in the cochlea. J Comp Neurol (2009) 1.25
Direct interaction with Rab11a targets the epithelial Ca2+ channels TRPV5 and TRPV6 to the plasma membrane. Mol Cell Biol (2006) 1.25
GB virus type C: a beneficial infection? J Clin Microbiol (2004) 1.24
Gitelman's syndrome: towards genotype-phenotype correlations? Pediatr Nephrol (2006) 1.24
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) 1.24
An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc Natl Acad Sci U S A (2006) 1.23
Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses (2002) 1.23
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 1.22
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood (2008) 1.21
Tissue involution and the acute phase response. Ann N Y Acad Sci (2003) 1.21
Diverse deafness mechanisms of connexin mutations revealed by studies using in vitro approaches and mouse models. Brain Res (2009) 1.20
Evaluation by high-resolution ultrasonography of endothelial function in brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Circ J (2002) 1.20
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
TBLR1 regulates the expression of nuclear hormone receptor co-repressors. BMC Cell Biol (2006) 1.14
Hyperbaric oxygen attenuates apoptosis and decreases inflammation in an ischemic wound model. J Invest Dermatol (2008) 1.14
Amnesia produced by altered release of neurotransmitters after intraamygdala injections of a protein synthesis inhibitor. Proc Natl Acad Sci U S A (2007) 1.13
GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microbes Infect (2003) 1.12
Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA (2004) 1.11
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 1.10
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin (2009) 1.10
Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J Immunol (2009) 1.10
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS (2009) 1.09
Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis (2007) 1.09
Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol (2010) 1.08
Digenic inheritance of non-syndromic deafness caused by mutations at the gap junction proteins Cx26 and Cx31. Hum Genet (2008) 1.08
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2012) 1.07
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun (2004) 1.06
Diencephalic damage decreases hippocampal acetylcholine release during spontaneous alternation testing. Learn Mem (2003) 1.06
Real-time polymerase chain reaction microRNA detection based on enzymatic stem-loop probes ligation. Anal Chem (2009) 1.06
Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology (2003) 1.05
Identification of Mycobacterium tuberculosis clinical isolates with altered phagocytosis by human macrophages due to a truncated lipoarabinomannan. J Biol Chem (2008) 1.05
Tissue kallikrein stimulates Ca(2+) reabsorption via PKC-dependent plasma membrane accumulation of TRPV5. EMBO J (2006) 1.05
The beta-glucuronidase klotho exclusively activates the epithelial Ca2+ channels TRPV5 and TRPV6. Nephrol Dial Transplant (2008) 1.05
HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS (2007) 1.04